Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to describe the expanding role of precision oncology and its applications in federal and public health settings
Upon completion of this activity, participants should be better able to apply current evidence-based guidelines to select, interpret, and apply results of biomarker testing in solid tumors
Upon completion of this activity, participants should be better able to evaluate recent clinical trial efficacy and safety data impacting biomarker-driven treatment decisions in patients with solid tumors
Upon completion of this activity, participants should be better able to assess recent guideline changes related to selecting and sequencing systemic therapies for solid tumors in advanced/metastatic and adjuvant settings
Upon completion of this activity, participants should be better able to identify strategies to monitor and mitigate adverse events associated with novel therapies in solid tumors